Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Prostate. 2014 Jul 22;74(13):1308–1319. doi: 10.1002/pros.22847

Figure 6.

Figure 6

Efficacy of the FAP-activated ERGETGP-S12ADT prodrug against human breast cancer xenograft models. (A) Animals bearing MDA-MB-231 xenografts were treated with three consecutive daily IV doses for 2 cycles initiated on a one week interval (days 0 and 7). While therapy showed a modest anti-tumor effect, this was not significantly different from vehicle-treated controls. (B) A significant inhibition of tumor growth was observed against MCF-7 xenografts in mice treated with the FAP-activated prodrug. Animals were received 3 cycles of 3 consecutive daily doses with a one week interval between cycle initiation (i.e., days 0, 7, and 13). (C) Representative H&E staining from MDA-MB-231 (left panel) and MCF-7 (right panel) breast cancer xenografts. Images taken at 10× magnification. Error bars represent +/− standard error. P-values ≤ 0.05 (*) are considered statistically significant.

HHS Vulnerability Disclosure